The role of blocking factors and antipaternal lymphocytotoxic antibodies in the success of pregnancy in patients with recurrent spontaneous abortion. 1992

J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
Department of Obstetrics and Gynecology, Medical College and Hospital National Taiwan University, Taipei, Republic of China.

OBJECTIVE To elucidate the role of mixed lymphocyte reaction blocking factors (BF) and complement-dependent antipaternal lymphocytotoxic antibodies on the outcome of pregnancy in unexplained recurrent spontaneous aborters. METHODS A controlled study of immunotherapy in which the treated group was immunized with the husband's or a third party donor's lymphocytes and the control group received autologous lymphocytes. METHODS Tertiary care institution. METHODS Forty-three patients in the control group and 48 patients in the treated group. METHODS The before and after immunization levels of BF and antipaternal lymphocytotoxic antibodies were measured. METHODS The existence or changing pattern of BF and antipaternal lymphocytotoxic antibodies levels before and after immunization had no influence on the pregnancy outcome in either group of patients. CONCLUSIONS Neither BF nor antipaternal lymphocytotoxic antibodies is essential for successful pregnancy. They probably reflect the immunological response of the mother to exposure to fetal antigens.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005220 Fathers Male parents, human or animal. Father
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000026 Abortion, Habitual Three or more consecutive spontaneous abortions. Abortion, Recurrent,Miscarriage, Recurrent,Recurrent Early Pregnancy Loss,Habitual Abortion,Habitual Abortions,Recurrent Abortion,Recurrent Abortions,Recurrent Miscarriage,Recurrent Miscarriages
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell

Related Publications

J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
January 1988, Lancet (London, England),
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
April 2001, American journal of reproductive immunology (New York, N.Y. : 1989),
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
April 1996, The journal of obstetrics and gynaecology research,
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
October 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
July 1991, Journal of reproductive immunology,
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
November 1983, Lancet (London, England),
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
October 2023, American journal of reproductive immunology (New York, N.Y. : 1989),
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
June 2000, Panminerva medica,
J L Hwang, and H N Ho, and Y S Yang, and C Y Hsieh, and T Y Lee, and T J Gill
September 1994, Clinical obstetrics and gynecology,
Copied contents to your clipboard!